Method for controlling the therapy of patients suffering from cardiac insufficiency by means of in vitro determination of threshold values of vasoactive peptides
AssigneeB.R.A.H.M.S GmbH
InventorAndreas Bergmann
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for controlling the therapeutic treatment of a patient suffering from cardiac insufficiency. In said method, it is determined how the concentration of at least one of the vasoactive peptides adrenomedullin (ADM), endothelin-1 (ET-1), and/or vasopressin (AVP) changes in the patient's blood after beginning the therapy, and the therapeutic measures are considered to be unsatisfactory and are modified in case said concentration does not decrease at all or not enough in relation to a threshold value for the respective vasoactive peptide.
Claims13
A method for guiding non-surgical therapeutic treatment of a patient suffering from chronic cardiac insufficiency, said method comprising determining the concentration of at least two inactive peptides each of which is derived from the same propeptide precursor as a vasoactive peptides selected from the group consisting of adrenomedullin (ADM), endothelin-1 (ET-1) and vasopressin (AVP) in the blood of the patient before and after beginning therapy and comparing said before- and after-concentrations for each of said at least two inactive peptides wherein the at least two inactive peptides determined are selected from the group consisting of MR-proADM, CT-proET-1 and CT-proAVP, wherein no reduction of said concentrations indicates that the therapeutic measures are unsatisfactory and the therapeutic measures are changed, and wherein a reduction in said concentration indicates successful therapy.
A method for guiding non-surgical therapeutic treatment options for a patient suffering from chronic cardiac insufficiency, comprising
- a) determining the concentrations of at least two inactive copeptides, each of which is formed from the same precursor as a vasoactive peptides selected from the group consisting of adrenomedullin (ADM), endothelin-1 (ET-1) and vasopressin (AVP) in the blood of the patient before therapy;
- b) determining the concentration of said at least two inactive peptides measured in step a), after beginning therapy;
- c) comparing the concentration of said at least two inactive peptides in the patient's blood before therapy to the concentration of said peptides after beginning therapy wherein the at least two inactive peptides determined are selected from the group consisting of MR-proADM, CT-proET-1 and CT-proAVP, wherein a reduction in the concentration of both of said peptides indicates that the therapy is effective and wherein no change or an increase in concentration indicates that the therapy is not effective.
Dependencies are inferred from the claim text.